DE60324936D1 - Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist - Google Patents

Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist

Info

Publication number
DE60324936D1
DE60324936D1 DE60324936T DE60324936T DE60324936D1 DE 60324936 D1 DE60324936 D1 DE 60324936D1 DE 60324936 T DE60324936 T DE 60324936T DE 60324936 T DE60324936 T DE 60324936T DE 60324936 D1 DE60324936 D1 DE 60324936D1
Authority
DE
Germany
Prior art keywords
group
amino acid
glucagon receptor
bicyclic
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324936T
Other languages
German (de)
English (en)
Inventor
Olivier Potterat
Ruediger Streicher
Klaus Wagner
Till Maurer
Juergen Mack
Stefan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Application granted granted Critical
Publication of DE60324936D1 publication Critical patent/DE60324936D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE60324936T 2002-07-17 2003-07-15 Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist Expired - Lifetime DE60324936D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02015907 2002-07-17
PCT/EP2003/007657 WO2004007535A1 (en) 2002-07-17 2003-07-15 Bicyclic oligopeptides and their use as glucagon receptor antagonists

Publications (1)

Publication Number Publication Date
DE60324936D1 true DE60324936D1 (de) 2009-01-08

Family

ID=30011078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324936T Expired - Lifetime DE60324936D1 (de) 2002-07-17 2003-07-15 Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist

Country Status (8)

Country Link
EP (1) EP1525218B1 (cg-RX-API-DMAC10.html)
JP (1) JP4616000B2 (cg-RX-API-DMAC10.html)
AT (1) ATE415415T1 (cg-RX-API-DMAC10.html)
AU (2) AU2003260306A1 (cg-RX-API-DMAC10.html)
CA (1) CA2489189A1 (cg-RX-API-DMAC10.html)
DE (1) DE60324936D1 (cg-RX-API-DMAC10.html)
ES (1) ES2316820T3 (cg-RX-API-DMAC10.html)
WO (2) WO2004007524A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
SG11201407316QA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of hyperglycemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139526A (en) * 1977-12-01 1979-02-13 Merck & Co., Inc. Somatostatin analogs

Also Published As

Publication number Publication date
JP2006505507A (ja) 2006-02-16
ATE415415T1 (de) 2008-12-15
CA2489189A1 (en) 2004-01-22
ES2316820T3 (es) 2009-04-16
AU2003260306A1 (en) 2004-02-02
JP4616000B2 (ja) 2011-01-19
WO2004007524A2 (en) 2004-01-22
EP1525218A1 (en) 2005-04-27
WO2004007535A1 (en) 2004-01-22
EP1525218B1 (en) 2008-11-26
AU2003246702A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
AU2010310665B2 (en) Peptidic GLP-2 agonists
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4
ATE517119T1 (de) Einzelketteninsulin
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EA200901108A1 (ru) Соагонисты глюкагоновых/glp-1-рецепторов
ATE549028T1 (de) Stabile analoga von glp-1
NO20011386D0 (no) Nye metoder for fremvisning av (poly)peptider/proteiner pÕ bakteriofage partikler via disulfidbindinger
ATE509618T1 (de) Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
JP6811190B2 (ja) プロテアーゼ耐性脂質付加glp−1類似体
ATE474850T1 (de) Analoga von peptiden der relaxin-superfamilie
KR20060065588A (ko) 면역 조절 활성, 항염증 활성 및 항바이러스 활성을 지니는펩티드 및 펩티도미메틱
WO2022177878A1 (en) Glucagon-like peptide-1 receptor antagonists
Karhu et al. Isolation of new ligands for orphan receptor MRGPRX1—hemorphins LVV-H7 and VV-H7
ATE415415T1 (de) Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist
Jinsmaa et al. Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes
DE60233654D1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
KR940007059A (ko) 변형된 혈소판 인자-4
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
ATE417061T1 (de) Scorpionpeptid als blutdrucksenkendes mittel
DE50310131D1 (de) Peptide mit hohem cysteingehalt
NZ761754B2 (en) Acylated oxyntomodulin peptide analog

Legal Events

Date Code Title Description
8364 No opposition during term of opposition